Servier Bio-Innovation
Clinical trials sponsored by Servier Bio-Innovation, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New immunotherapy cocktails aim to shrink tough lung tumors Results expected Apr 2027 (estimated)
- New drug combo targets Hard-to-Treat cancers with MTAP deletion Results expected May 2027 (estimated)
- New antibody combo takes on Hard-to-Treat stomach cancers Results expected Aug 2027 (estimated)
-
Experimental cancer drug trial halted early
Disease control Stopped earlyThis study tested a new drug called PRS-344/S095012 in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was stopped early, and only 46 people took part.
Phase 1/2 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising cancer combo trial halted after just 7 patients
Disease control Stopped earlyThis early-phase trial tested a three-drug combination (ivosidenib, nivolumab, and ipilimumab) in 7 people with advanced bile duct cancer that has a specific IDH1 mutation. The goal was to check safety and find the right dose, but the study was stopped early by the sponsor before…
Phase 1/2 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New hope for hard-to-treat blood cancers? early trial stopped short
Disease control Stopped earlyThis study tested a new drug called S227928, alone or with another drug (venetoclax), in people with certain blood cancers (AML, MDS/AML, or CMML) that returned or didn't respond to prior therapy. The goal was to find a safe dose and see if it helps. The trial was terminated earl…
Phase 1/2 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC